Increased use of digitization in clinical trials could benefit research sites and the entire clinical trial enterprise by making operations and planning more collaborative and less complex, says Jim Reilly, vice president, Vault R&D and Quality, with Veeva Systems.
Fresh off Veeva’s announcement with Boehringer Ingelheim about its role as part of the biopharmaceutical company’s Medicine Excellence initiative to harness technology with the aim of building a “One Medicine Platform” and unifying development processes and data in a centralized platform, Reilly thinks such digitization projects are the wave of the future.
“This is going to result in simplifying information exchange for everyone,” Reilly says. It will make information more accessible and less “request-based,” he adds. Boehringer Ingelheim will be able to operate more efficiently by unifying data processes across sites and with patients, he says.
Digitization could also translate into faster clinical trials and a better patient experience, Reilly says. “Our stated goals for the industry are to make trials 25% faster and reduce costs,” he notes. “This is an opportunity to bring forward a new way of working.”
Reilly also believes digitization will be instrumental in helping realize more of the benefits of hybrid and fully decentralized clinical trials and help “address some of the interoperability” issues that may have slowed progress in this arena.
Author: Michael Causey
